Search | Clinical Trials Finder

Conditions: Healthy Participants
Interventions: BMS-986322, Placebo for BMS-986322; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Dyskinesia, Parkinson's Disease
Interventions: AVP-923-45, Placebo; Drug
Lead sponsor: Avanir Pharmaceuticals; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Chicago, Illinois • Portland, Oregon

Conditions: Healthy Volunteers, Atopic Disease
Interventions: XmAb7195, Placebo; Drug
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Non Cystic Fibrosis Bronchiectasis
Interventions: Ciprofloxacin dispersion for inhalation, Placebo; Drug
Lead sponsor: Aradigm Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 25
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Sacramento, California + 22 more

Conditions: Diabetes, Obesity
Interventions: PF-06882961, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 38
States / cities: Phoenix, Arizona • Searcy, Arkansas • Montclair, California + 31 more

Conditions: Vasomotor Symptoms Associated With Menopause
Interventions: Bazedoxifene/Conjugated Estrogen; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 40 Years to 64 Years · Female only
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 7
States / cities: Phoenix, Arizona • Fort Myers, Florida • North Port Richey, Florida + 4 more

Conditions: Metastatic BRCA Hereditary Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Triple-Negative Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Cisplatin, Laboratory Biomarker Analysis, Placebo Administration, Veliparib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 798
States / cities: Anchorage, Alaska • Fort Smith, Arkansas • Hot Springs, Arkansas + 542 more

Conditions: Methamphetamine Use Disorder
Interventions: Sham TMS, Active TMS; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Healthy Volunteer Study, Healthy Adults, Healthy Participants, Asthma
Interventions: PF-08103402, Placebo, Midazolam; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Postherpetic Neuralgia, Diabetic Neuropathy, Complex Regional Pain Syndrome, Carpal Tunnel Syndrome, HIV Neuropathy, Idiopathic Sensory Neuropathy, Peripheral Neuropathy
Interventions: Placebo Capsules + Placebo Patch, Placebo capsules + Lidoderm®, Gabapentin + Placebo, Gabapentin + Lidoderm®, Gabapentin 300 mg capsules 1800 mg/day + placebo patch, Gabapentin 1800 mg/day + Lidoderm patch; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 7
States / cities: Birmingham, Alabama • Hueytown, Alabama • Phoenix, Arizona + 4 more

Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: erlotinib hydrochloride, paclitaxel, carboplatin, bevacizumab; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 108
States / cities: Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 65 more

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: ¹³C-Methacetin Breath Test, BMS-986036, BreathID MCS device; Combination Product · Drug · Device
Lead sponsor: Meridian Bioscience, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Humble, Texas

Conditions: Obstructive Sleep Apnea
Interventions: Eszopiclone, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 64 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: COPD
Interventions: Arformoterol tartrate inhalation solution, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 35 Years and older
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 31
States / cities: Encinitas, California • Long Beach, California • Brandon, Florida + 28 more

Conditions: Major Depressive Disorder
Interventions: AV-101, Placebo; Drug
Lead sponsor: VistaGen Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 22
States / cities: Garden Grove, California • Los Angeles, California • National City, California + 18 more

Conditions: Attention-Deficit/Hyperactivity Disorder
Interventions: ABT-089, Placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 23
States / cities: Mesa, Arizona • Lafayette, California • Oceanside, California + 20 more

Conditions: Primary Hyperoxaluria
Interventions: Oxalobacter formigenes, Placebo; Biological · Drug
Lead sponsor: OxThera; Industry
Eligibility: 2 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Smoking Cessation, Pregnancy
Interventions: Bupropion SR, placebo, smoking cessation counseling; Drug · Behavioral
Lead sponsor: Watching Over Mothers & Babies Foundation; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Pre Diabetes, Insulin Resistant
Interventions: salsalate, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 30 Years to 60 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Stanford, California

Conditions: Obesity, Heart Failure
Interventions: NNC0487-0111, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 5,610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 206
States / cities: Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 173 more

Conditions: Rheumatoid Arthritis
Interventions: pioglitazone, Sublingual nitroglycerine; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 21 Years to 100 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Healthy Volunteer Study
Interventions: SCO-120, matching placebo; Drug
Lead sponsor: Sun Pharma Advanced Research Company Limited; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Dilworth, Minnesota • Creve Coeur, Missouri

Conditions: Migraine Headache
Interventions: Placebo, Zolmitriptan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 1,653 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 46
States / cities: Phoenix, Arizona • Fresno, California • Fullerton, California + 43 more

Conditions: Multiple Sclerosis
Interventions: Teriflunomide, Placebo (for teriflunomide), Interferon-β [IFN-β], Glatiramer Acetate [GA]; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Search by objective public record fields.

A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese Descent

Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients

Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4)

A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY

Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Symptoms Associated With Menopause

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

Testing an Accelerated TMS Protocol for Methamphetamine Use Disorder

A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma

A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions

Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer

Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced Trials

The Effect of Eszopiclone on the Arousal Threshold in Sleep Apnea Syndrome

A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression

A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Phase 2/3 Oxabact Study

Bupropion for Smoking Cessation in Pregnancy

Beneficial Effect of Salicylates: Insulin Action, Secretion or Clearance?

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease

Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subjects

Zomig - Treatment of Acute Migraine Headache in Adolescents

Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis